Familial Mediterranean fever is the most common monogenic auto-inflammatory disease in the world. It mainly affects people originating from the Mediterranean region. The mutated gene is MEFV, which codes for pyrin. Transmission is autosomal recessive. Patients present with recurrent attacks of fever since childhood associated with abdominal and/or thoracic pain lasting an average of 2-3days and a biological inflammatory syndrome. Other symptoms include arthralgia or arthritis in large joints such as the knees and ankles, myalgia in the lower limbs and pseudo-erysipelas in the ankles. The most serious complication is inflammatory amyloidosis, which can lead to kidney failure. Treatment is based on colchicine, which helps to prevent flares and the onset of renal amyloidosis. This paper proposes national guidelines for the diagnosis, management and follow-up of familial Mediterranean fever in France, where we estimate there are between 5000 and 10,000 patients with the disease at all stages of life. The diagnosis is suspected on the basis of clinical and anamnestic factors and confirmed by genetic analysis. These guidelines also suggest a "treat-to-target" approach to disease management, particularly in case of suspected colchicine resistance - a very rare situation that should remain a diagnosis of elimination, especially after colchicine compliance has been verified. Two special situations are also addressed in these guidelines: kidney failure and pregnancy.
Keywords: AA amyloidosis; Amylose AA; Amylose inflammatoire; Auto-inflammatory diseases; Colchicine; Familial Mediterranean fever; Fièvre Méditerranéenne familiale; Inflammasome; Inflammation; Inflammatory amyloidosis; MEFV; Maladie auto-inflammatoire; Protéine sérique amyloïde A sérique; Pyrin; Pyrine; Serum amyloid A protein; Traitement ciblé; Treat-to-target strategy.
Copyright © 2023. Published by Elsevier Masson SAS.